Search Results - "Ogiso, Atsuko"

Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04) by Futamura, Manabu, Ishihara, Kazuhiro, Nagao, Yasuko, Ogiso, Atsuko, Niwa, Yoshimi, Nakada, Takumi, Kawaguchi, Yoshihiro, Ikawa, Ai, Kumazawa, Iwao, Mori, Ryutaro, Kitazawa, Mai, Hosono, Yoshiki, Kuno, Masashi, Kawajiri, Mana, Nakakami, Akira, Takeuchi, Makoto, Morikawa, Akemi, Tokumaru, Yoshihisa, Katagiri, Yasuo, Asano, Yoshimasa, Mushika, Yoshinori, Shimokawa, Toshio, Matsuhasih, Nobuhisa

“…Background Nanoparticle albumin-bound paclitaxel (nab-PTX) is a promising antibody partner for anti-human epidermal growth factor receptor 2 (HER2). We…”
Get full text

Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study by Iihara, Hirotoshi, Shimokawa, Mototsugu, Bando, Hiroko, Niwa, Yoshimi, Mizuno, Yutaka, Kawaguchi, Yoshihiro, Kitahora, Mika, Murakami, Akari, Kawai, Masaaki, Ishida, Kazushige, Takeuchi, Makoto, Ishihara, Kazuhiro, Iyoda, Tomokazu, Nakada, Takumi, Ogiso, Atsuko, Kojima, Yasuyuki, Kumagai, Fumiyoshi, Sawa, Aya, Mori, Ryutaro, Higuchi, Kosuke, Furuta, Tomoko, Kamei, Yoshiaki, Tsuchiya, Masami, Terasaki, Azusa, Yamamoto, Senri, Kitazawa, Mai, Okazaki, Mai, Suzuki, Akio, Futamura, Manabu

“…Background: Trastuzumab deruxtecan is classified as an anticancer agent that poses a moderate emetic risk in the international guidelines for antiemetic…”
Get full text